{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:42:06Z","timestamp":1786250526080,"version":"build-2736575974"},"reference-count":65,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T00:00:00Z","timestamp":1786060800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"crossref","award":["PI23\/03010"],"award-info":[{"award-number":["PI23\/03010"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"crossref"}]},{"award":["PI23\/03010"],"award-info":[{"award-number":["PI23\/03010"]}],"id":[{"id":"https:\/\/ror.org\/00ca2c886","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: External validation of predictive models is needed in new populations after their implementation. Objective: We aimed to validate and compare the performance of the BCN-MRI PM and ERSPC-MRI PM in an Ibero-American population. Methods: We conducted a retrospective analysis of 540 men with suspected PCa who underwent MRI and prostate biopsy in 2025. Individual csPCa risk estimates were calculated using the online calculators for the BCN-MRI PM and ERSPC-MRI PM. The reference standard outcome was the rate of avoided biopsies. Calibration, discrimination of csPCa, net benefit, and clinical utility were analyzed with R software. Results: All participants underwent MRI and prostate biopsy. The median age was 66 years (95% CI 61\u201371). The overall csPCa detection rate was 55.7%. The BCN-MRI PM demonstrated good calibration, with close agreement between predicted and observed csPCa probabilities, whereas the ERSPC-MRI PM underestimated risk in the intermediate-probability range. Discrimination for csPCa was significantly better with the BCN-MRI PM (AUC, 0.807; 95% CI 0.771\u20130.843) than with the ERSPC-MRI PM (AUC, 0.764; 95% CI 0.724\u20130.803; p &lt; 0.001). Decision curve analysis showed a greater net benefit for the BCN-MRI PM than for the ERSPC-MRI PM and the strategy of biopsying all men. Clinical utility curves demonstrated a more favorable balance between avoided biopsies and missed csPCa cases across threshold probabilities. At a sensitivity of 95%, the BCN-MRI PM achieved a specificity of 38.9% (95% CI, 32.5\u201345.1%) compared with 30.1% (95% CI, 24.6\u201335.7%) for the ERSPC-MRI PM, avoiding 21.5% and 16.3% of biopsies, respectively (p = 0.043). The performance of both models was also evaluated according to PI-RADS category and participating center. Conclusions: In this Ibero-American cohort, the BCN-MRI PM demonstrated superior calibration and overall clinical performance compared with the ERSPC-MRI PM.<\/jats:p>","DOI":"10.3390\/cancers18162541","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T11:44:53Z","timestamp":1786103093000},"page":"2541","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Comparative Validation and Performance of the Barcelona- and ERSPC-MRI Predictive Model in an Ibero-American Population of Men Suspected of Having Prostate Cancer"],"prefix":"10.3390","volume":"18","author":[{"given":"Nahuel","family":"Paesano","sequence":"first","affiliation":[{"name":"Uro-Radiology Unit, Cl\u00ednica Creu Blanca, 08034 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violeta","family":"Catal\u00e1","sequence":"additional","affiliation":[{"name":"Uro-Radiology Unit, Cl\u00ednica Creu Blanca, 08034 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Camean","sequence":"additional","affiliation":[{"name":"Department of Surgical Oncology, Instituto Alexander Fleming, Buenos Aires 1426, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom\u00e1s Eduardo","family":"Olmedo","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Cl\u00ednico Universidad de Chile, Independencia, Santiago 8380456, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaqu\u00edn Ignacio","family":"Gurovich","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Cl\u00ednico Universidad de Chile, Independencia, Santiago 8380456, Chile"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximiliano","family":"Ringa","sequence":"additional","affiliation":[{"name":"Department of Urology, Hospital Alem\u00e1n, Buenos Aires 1424, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6049-8697","authenticated-orcid":false,"given":"Berta","family":"Mir\u00f3","sequence":"additional","affiliation":[{"name":"Bioinformatics and Statistical Unit, Vall d\u2019Hebron Research Institute, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Regis","sequence":"additional","affiliation":[{"name":"Research Group in Urology, Vall d\u2019Hebron Research Institute, 08035 Barcelona, Spain"},{"name":"Department of Urology, Hospital Universitario Vall d\u2019Hebron, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Mendez","sequence":"additional","affiliation":[{"name":"Research Group in Urology, Vall d\u2019Hebron Research Institute, 08035 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Trilla","sequence":"additional","affiliation":[{"name":"Research Group in Urology, Vall d\u2019Hebron Research Institute, 08035 Barcelona, Spain"},{"name":"Department of Urology, Hospital Universitario Vall d\u2019Hebron, 08035 Barcelona, Spain"},{"name":"Department of Surgery, Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Morote","sequence":"additional","affiliation":[{"name":"Research Group in Urology, Vall d\u2019Hebron Research Institute, 08035 Barcelona, Spain"},{"name":"Department of Surgery, Universitat Aut\u00f2noma de Barcelona, 08193 Bellaterra, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,7]]},"reference":[{"key":"ref_1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1056\/NEJMoa0810084","article-title":"Screening and prostate-cancer mortality in a randomized European study","volume":"360","author":"Schroder","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1097\/JU.0000000000002696","article-title":"Results from 22 years of Followup in the G\u00f6teborg Randomized Population-Based Prostate Cancer Screening Trial","volume":"208","author":"Godtman","year":"2022","journal-title":"J. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1056\/NEJMoa2503223","article-title":"European Study of Prostate Cancer Screening\u201423-Year Follow-up","volume":"393","author":"Roobol","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.eururo.2014.12.006","article-title":"Opportunistic testing versus organized prostate-specific antigen screening: Outcome after 18 years in the G\u00f6teborg randomized population-based prostate cancer screening trial","volume":"68","author":"Godtman","year":"2015","journal-title":"Eur. Urol."},{"key":"ref_6","first-page":"327","article-title":"Early Detection of Prostate Cancer in 2020 and Beyond: Facts and ecommendations for the European Union and the European Commission","volume":"79","author":"Hogenhout","year":"2020","journal-title":"Eur. Urol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.eururo.2021.07.024","article-title":"Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021","volume":"80","author":"Roobol","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_8","unstructured":"Cornford, P., Tilki, D., van den Bergh, R.C.N., Eberli, D., De Meerleer, G., De Santis, M., Gillessen, S., Henry, A.M., van Leenders, G.J.L.H., and Oldenburg, J. (2026, June 09). EAU-EANM-ESTRO-ESUP-ISUP-SIOG Guidelines on Prostate Cancer. Available online: http:\/\/uroweborg\/guidelines\/."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.euo.2021.06.006","article-title":"A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer","volume":"4","author":"Hogenhout","year":"2021","journal-title":"Eur. Urol. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1016\/j.euf.2022.06.008","article-title":"Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme","volume":"8","author":"Alterbeck","year":"2022","journal-title":"Eur. Urol. Focus."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.euros.2021.11.002","article-title":"Reducing Biopsies and Magnetic Resonance Imaging Scans During the Diagnostic Pathway of Prostate Cancer: Applying the Rotterdam Prostate Cancer Risk Calculator to the PRECISION Trial Data","volume":"36","author":"Remmers","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/bco2.146","article-title":"Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification","volume":"3","author":"Davik","year":"2022","journal-title":"BJUI Compass"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/bco2.230","article-title":"A risk-organised model for clinically significant prostate cancer early detection","volume":"4","author":"Morote","year":"2023","journal-title":"BJUI Compass"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"115.e1","DOI":"10.1016\/j.urolonc.2023.09.020","article-title":"Reducing the demand for magnetic resonance imaging scans and prostate biopsies during the early detection of clinically significant prostate cancer: Applying the Barcelona risk-stratified pathway in Catalonia","volume":"42","author":"Morote","year":"2024","journal-title":"Urol. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.eururo.2021.12.021","article-title":"Cost-Effectiveness of the Stockholm3 Test and Magnetic Resonance Imaging in Prostate Cancer Screening: A Microsimulation Study","volume":"82","author":"Hao","year":"2022","journal-title":"Eur. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Morote, J., Borque-Fernando, \u00c1., Esteban, L.M., Celma, A., Campistol, M., Mir\u00f3, B., M\u00e9ndez, O., and Trilla, E. (2024). Investigating Efficient Risk-Stratified Pathways for the Early Detection of Clinically Significant Prostate Cancer. J. Pers. Med., 14.","DOI":"10.3390\/jpm14020130"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Triquell, M., Campistol, M., Celma, A., Regis, L., Cuadras, M., Planas, J., Trilla, E., and Morote, J. (2022). Magnetic Resonance Imaging-Based Predictive Models for Clinically Significant Prostate Cancer: A Systematic Review. Cancers, 14.","DOI":"10.3390\/cancers14194747"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/s41391-024-00852-w","article-title":"Risk calculators for the detection of prostate cancer: A systematic review","volume":"27","author":"Denijs","year":"2024","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41391-025-01014-2","article-title":"Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: A systematic review and meta-analysis","volume":"29","author":"Boakye","year":"2026","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1093\/ckj\/sfaa188","article-title":"External validation of prognostic models: What, why, how, when and where","volume":"14","author":"Ramspek","year":"2021","journal-title":"Clin. Kidney J."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1007\/s12350-022-02994-7","article-title":"Statistical methods for validation of predictive models","volume":"29","author":"Diniz","year":"2022","journal-title":"J. Nucl. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.eururo.2018.07.031","article-title":"Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators","volume":"75","author":"Alberts","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/bju.14958","article-title":"External validation of novel magnetic resonance imaging-based models for prostate cancer prediction","volume":"125","author":"Radtke","year":"2020","journal-title":"BJU Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00345-020-03177-0","article-title":"Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men","volume":"39","author":"Chen","year":"2021","journal-title":"World J. Urol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"4109","DOI":"10.1007\/s00345-021-03770-x","article-title":"External validation of two MRI-based risk calculators in prostate cancer diagnosis","volume":"39","author":"Petersmann","year":"2021","journal-title":"World J. Urol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1016\/j.ejso.2021.04.033","article-title":"Rotterdam mobile phone app including MRI data for the prediction of prostate cancer: A multicenter external validation","volume":"47","author":"Lombardo","year":"2021","journal-title":"Eur. J. Surg. Oncol."},{"key":"ref_27","first-page":"1","article-title":"External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort","volume":"41","author":"Palsdottir","year":"2022","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1111\/bju.16163","article-title":"Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres","volume":"133","author":"Davik","year":"2024","journal-title":"BJU Int."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.euros.2023.03.013","article-title":"Comparison of Rotterdam and Barcelona Magnetic Resonance Imaging Risk Calculators for Predicting Clinically Significant Prostate Cancer","volume":"53","author":"Morote","year":"2023","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e241516","DOI":"10.1001\/jamanetworkopen.2024.1516","article-title":"Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk","volume":"7","author":"Patel","year":"2024","journal-title":"JAMA Netw. Open."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Morote, J., Borque-Fernando, \u00c1., Triquell, M., Campistol, M., Celma, A., Regis, L., Abascal, J.M., Servian, P., Planas, J., and Mendez, O. (2022). A Clinically Significant Prostate Cancer Predictive Model Using Digital Rectal Examination Prostate Volume Category to Stratify Initial Prostate Cancer Suspicion and Reduce Magnetic Resonance Imaging Demand. Cancers, 14.","DOI":"10.3390\/cancers14205100"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Morote, J., Borque-Fernando, A., Triquell, M., Celma, A., Regis, L., Escobar, M., Mast, R., de Torres, I.M., Semidey, M.E., and Abascal, J.M. (2022). The Barcelona Predictive Model of Clinically Significant Prostate Cancer. Cancers, 14.","DOI":"10.3390\/cancers14061589"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1007\/s00345-024-05092-0","article-title":"External validation of the Barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors","volume":"42","author":"Morote","year":"2024","journal-title":"World J. Urol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1590\/s1677-5538.ibju.2024.0204","article-title":"Validation of the Barcelona-MRI predictive model when PI-RADS v2.1 is used with transperineal prostate biopsies","volume":"50","author":"Morote","year":"2024","journal-title":"Int. Braz. J. Urol."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Paesano, N., Catal\u00e1, V., Tcholakian, L., Alomar, X., Barranco, M.\u00c1., Hern\u00e1ndez-Mancera, J., Mir\u00f3, B., Trilla, E., and Morote, J. (2025). Validation of the Barcelona Magnetic Resonance Imaging Predictive Model for Significant Prostate Cancer Detection in Men Undergoing Mapping per 0.5 Mm-Core Targeted Biopsies of Suspicious Lesions and Perilesional Areas. Cancers, 17.","DOI":"10.3390\/cancers17030473"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e70198","DOI":"10.1002\/bco2.70198","article-title":"European validation of the Barcelona magnetic resonance predictive model for significant prostate cancer detection in prostate biopsies","volume":"7","author":"Morote","year":"2026","journal-title":"BJUI Compass"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Paesano, N., Camean, J., Ringa, M., L\u00f3pez-Silva, M., Koren, G., Olmedo, T.E., Gurovich, J.I., Bravo-Castro, E.I., Catal\u00e1, V., and Contreras, P. (2026). External Validation and Clinical Impact of the Barcelona Predictive Models for Detecting Significant Prostate Cancer in Prostate Biopsies in an Ibero-American Population. Cancers, 18.","DOI":"10.3390\/cancers18111810"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1007\/s00330-011-2377-y","article-title":"ESUR prostate MR guidelines 2012","volume":"22","author":"Barentsz","year":"2012","journal-title":"Eur. Radiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","article-title":"Prostate Imaging Reporting and Data System Version 2.1: 2019 Update of Prostate Imaging Reporting and Data System Version 2","volume":"76","author":"Turkbey","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1038\/s41391-021-00417-1","article-title":"Cancer detection rates of the PI-RADSv2.1 assessment categories: Systematic review and meta-analysis on lesion level and patient level","volume":"25","author":"Oerther","year":"2022","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","volume":"40","author":"Epstein","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.eururo.2015.06.046","article-title":"A Contemporary Prostate Cancer Grading System: A Validated Alternative to the Gleason Score","volume":"69","author":"Epstein","year":"2016","journal-title":"Eur. Urol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.eururo.2013.03.030","article-title":"Standards of reporting for MRI-targeted biopsy studies (START) of the prostate: Recommendations from an International Working Group","volume":"64","author":"Moore","year":"2013","journal-title":"Eur. Urol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"70","DOI":"10.21037\/tau.2017.12.31","article-title":"MRI in early prostate cancer detection: How to manage indeterminate or equivocal PI-RADS 3 lesions","volume":"7","author":"Schoots","year":"2018","journal-title":"Transl. Androl. Urol."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Osses, D.F., Arsov, C., Schimm\u00f6ller, L., Schoots, I.G., van Leenders, G.J.L.H., Esposito, I., Remmers, S., Albers, P., and Roobol, M.J. (2020). Equivocal PI-RADS Three Lesions on Prostate Magnetic Resonance Imaging: Risk Stratification Strategies to Avoid MRI-Targeted Biopsies. J. Pers. Med., 10.","DOI":"10.3390\/jpm10040270"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ejrad.2019.02.031","article-title":"Which clinical and radiological characteristics can predict clinically significant prostate cancer in PI-RADS 3 lesions? A retrospective study in a high-volume academic center","volume":"114","author":"Hermie","year":"2019","journal-title":"Eur. J. Radiol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/21681805.2020.1798503","article-title":"Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center","volume":"54","author":"Musi","year":"2020","journal-title":"Scand. J. Urol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1007\/s00330-020-06958-8","article-title":"Clinico-radiological characteristic-based machine learning in reducing unnecessary prostate biopsies of PI-RADS 3 lesions with dual validation","volume":"30","author":"Kan","year":"2020","journal-title":"Eur. Radiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.21037\/tau-19-755","article-title":"Combining clinical and MRI data to manage PI-RADS 3 lesions and reduce excessive biopsy","volume":"9","author":"Yang","year":"2020","journal-title":"Transl. Androl. Urol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/j.euf.2019.06.014","article-title":"Prostate Imaging Reporting and Data System 3 Category Cases at Multiparametric Magnetic Resonance for Prostate Cancer: A Systematic Review and Meta-analysis","volume":"6","author":"Maggi","year":"2020","journal-title":"Eur. Urol. Focus"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1111\/ajco.13347","article-title":"Clinical factors for predicting malignancy in patients with PSA < 10 ng\/mL and PI-RADS 3 lesions","volume":"17","author":"Sonmez","year":"2021","journal-title":"Asia Pac. J. Clin. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41598-020-80749-5","article-title":"Evaluation of a multiparametric MRI radiomic-based approach for stratification of equivocal PI-RADS 3 and upgraded PI-RADS 4 prostatic lesions","volume":"11","author":"Brancato","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.euf.2019.11.012","article-title":"The Value of Prostate-specific Antigen Density for Prostate Imaging-Reporting and Data System 3 Lesions on Multiparametric Magnetic Resonance Imaging: A Strategy to Avoid Unnecessary Prostate Biopsies","volume":"7","author":"Radtke","year":"2021","journal-title":"Eur. Urol. Focus"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1002\/cncr.34355","article-title":"Multi-institutional analysis of clinical and imaging risk factors for detecting clinically significant prostate cancer in men with PI-RADS 3 lesions","volume":"128","author":"Fang","year":"2022","journal-title":"Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s00345-025-05649-7","article-title":"Optimizing biopsy decisions in PI-RADS 3 lesions: Cross-institutional validation of a local clinical risk model","volume":"43","author":"Deniffel","year":"2025","journal-title":"World J. Urol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1038\/s41585-022-00638-6","article-title":"Serum PSA-based early detection of prostate cancer in Europe and globally: Past, present and future","volume":"19","author":"Albreht","year":"2022","journal-title":"Nat. Rev. Urol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e13734","DOI":"10.1111\/and.13734","article-title":"Can the combination of biparametric magnetic resonance imaging and PSA-related indicators predict the prostate biopsy outcome","volume":"52","author":"Zhu","year":"2020","journal-title":"Andrologia"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Peng, Y., Song, Y., and Wang, H. (2021). Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer. Front. Cell Dev. Biol., 9.","DOI":"10.3389\/fcell.2021.723466"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1097\/RLU.0000000000006309","article-title":"The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis","volume":"51","author":"Mourato","year":"2026","journal-title":"Clin. Nucl. Med."},{"key":"ref_60","first-page":"31","article-title":"Integrated multi-omics profiling of immune microenvironment and drug resistance signatures for precision prognosis in prostate cancer","volume":"8","author":"Li","year":"2025","journal-title":"Cancer Drug Resist."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jbi.2015.05.001","article-title":"Improving patient Prostate cancer risk assessment: Moving from static, globally-applied to dynamic, practice-specific risk calculators","volume":"56","author":"Strobl","year":"2015","journal-title":"J. Biomed. Inform."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Checcucci, E., Rosati, S., De Cillis, S., Giordano, N., Volpi, G., Granato, S., Zamengo, D., Verri, P., Amparore, D., and De Luca, S. (2023). Machine-Learning-Based Tool to Predict Target Prostate Biopsy Outcomes: An Internal Validation Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12134358"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Malerba, S., Vladimirov, M., Goyal, A., Dulskas, A., Bau\u0161ys, A., Cwalinski, T., Girnyi, S., Skokowski, J., Duka, R., and Molchanov, R. (2026). Artificial Intelligence Applications in Gastric Cancer Surgery: Bridging Early Diagnosis and Responsible Precision Medicine. J. Clin. Med., 15.","DOI":"10.3390\/jcm15062208"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ymeth.2022.03.005","article-title":"A federated learning method for real-time emotion state classification from multi-modal streaming","volume":"204","author":"Nandi","year":"2022","journal-title":"Methods"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"3551","DOI":"10.1038\/s41598-022-07186-4","article-title":"Federated learning for multi-center imaging diagnostics: A simulation study in cardiovascular disease","volume":"12","author":"Linardos","year":"2022","journal-title":"Sci. Rep."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2541\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,9]],"date-time":"2026-08-09T04:22:26Z","timestamp":1786249346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/16\/2541"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,7]]},"references-count":65,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["cancers18162541"],"URL":"https:\/\/doi.org\/10.3390\/cancers18162541","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,7]]}}}